A collecting system is provided that can include a probe configured to collect pathogens from a surrounding fluid, an elution chamber containing a liquid solvent and configured to receive the probe to elute the pathogens collected on the probe using the liquid solvent, and a heater configured to lyse the pathogens to release the genetic material of the pathogens into the liquid solvent.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
B01L 7/00 - Appareils de chauffage ou de refroidissement; Dispositifs d'isolation thermique
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
The present disclosure relates to methods and compositions for enhanced assessment of exogenous polynucleotide and/or polypeptide-mediated transcriptional perturbations at high throughput and single cell/droplet levels of resolution. In embodiments, nucleic acid fusions of exogenous polynucleotide(s) and associated target transcript(s) are produced within individually sequestered or discretely identifiable cells/lysates and analyzed for exogenous polynucleotide mediated perturbations across a vast population of droplets/cells within individual reactions. Kits for performance of the methods are also provided.
Provided herein are genetic circuits and encoded RNA transcripts that produce an output molecule in response to an RNA cleavage event that removes a degradation signal. In some embodiments, the genetic circuits described herein may be used for detecting RNA cleaver activities (e.g., in a cell). Methods of using the genetic circuits described herein in diagnostic or therapeutic applications are also provided.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/67 - Méthodes générales pour favoriser l'expression
In one aspect, embodiments disclosed herein are directed to engineered CRISPRCas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wild type. In certain example embodiments, the CRISPR-Cas effector protein is a Type II effector protein. In certain other example embodiments, the Type V effector protein is Cas9 or an orthologs or engineered variant thereof. Example Cas9 proteins suitable for use in the embodiments disclosed herein are discussed in further detail below.
This disclosure provides a method for imaging lymph nodes and lymphatic vessels without a contrast agent. The method includes providing, using an optical source, an infrared illumination to a region of a subject having at least one lymphatic component, detecting a reflected portion of the infrared illumination directly reflected from the region using a sensor positioned thereabout, and generating at least one image indicative of the at least one lymphatic component in the subject using the reflected portion of the infrared illumination.
G01N 21/35 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
Meta-lens based ocular imaging, near-eye display, and eye-tracking systems are described. The systems can include a single focusing optic and an integrated circuit that provides illumination light and includes an imaging array. The focusing optic includes meta-atoms formed on a substrate. The systems may have no moving parts and achieve imaging or image-projection fields-of-view approaching or exceeding 180 degrees. Because of their low part count, the systems can be robust and have a very small form factor.
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
A61B 3/12 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p.ex. ophtalmoscopes
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
G02B 27/00 - Systèmes ou appareils optiques non prévus dans aucun des groupes ,
Systems and methods related to drug delivery are provided. In one arrangement, a fluid is administered to a subject in drinkable form, which can partially or fully solidify in the stomach or another area of the gastrointestinal tract to form a drug release article or composition.
Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel TnpB polypeptides and a reprogrammable targeting nucleic acid component and methods and application of use are provided.
A method can include providing a first neural network connected to a second neural network. The first neural network can represent B+11 and the second neural network can represent electrical properties. The method can include training the first neural network and the second neural network jointly. The method can include determining, from the trained first neural network and the trained second neural network B+11, a prediction of and electrical properties at one or more predetermined locations. The method can include outputting the prediction of B+11 and EP.
Described herein are systems and methods for the generation of bio-based plasticizers from lignin from 4-hydroxybenzoic acid (H), vanillic acid (G) and syringic acid (S) obtained via oxidative depolymerization of lignin substrates. Chemical and electrochemical methods are described for catalytic reductive coupling of sulfonate derivatives of H, G and S to generate all possible homo- and cross-coupling products. Advantageously, the provided systems and methods allow for the generation of renewable plasticizers that exhibit performance advantages relative to established petroleum-based phthalate ester plasticizers.
B01J 23/89 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du cuivre ou des métaux du groupe du fer combinés à des métaux nobles
C07C 303/08 - Préparation d'esters ou d'amides d'acides sulfuriques; Préparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'acides sulfoniques ou de leurs halogénures par substitution d'atomes d'hydrogène par des groupes sulfo ou halogénosulfonyle par réaction avec des acides halogénosulfoniques
An electrochemical device includes a transition metal oxide cathode, such as LiNi0.8Co0.1Mn0.1O2, and an electrolyte. The electrolyte includes N, N-dimethyltrifluoromethane-sulfonamide (DMTMSA) and lithium bis(fluorosulfonyl)imide (LiFSI). The DMTMSA and LiFSI may be either the primary component of the electrolyte or an additive in the electrolyte. The electrochemical device may also include a graphite anode or a lithium metal anode. With a lithium metal anode, the electrochemical device has an initial specific capacity of at least 231 mAh g−1. Over at least 100 cycles (upper cut-off voltage of 4.7±0.05 V vs. Li/Li+), the electrochemical device maintains an average specific capacity of at least 88% of the initial specific capacity and an average Coulombic efficiency of at least about 99.65%.
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p.ex. LiMn2O4 ou LiMn2OxFy
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p.ex. LiNiO2, LiCoO2 ou LiCoOxFy
Methods, systems, and computer program products for translating text using generated visual representations and artificial intelligence are provided herein. A computer-implemented method includes generating a tokenized form of at least a portion of input text in a first language; generating at least one visual representation of at least a portion of the input text using a first set of artificial intelligence techniques; generating a tokenized form of at least a portion of the at least one visual representation; and generating an output including a translated version of the input text into at least a second language by processing, using a second set of artificial intelligence techniques, at least a portion of the tokenized form of the at least a portion of the input text and at least a portion of the tokenized form of the at least a portion of the at least one visual representation.
G06F 40/58 - Utilisation de traduction automatisée, p.ex. pour recherches multilingues, pour fournir aux dispositifs clients une traduction effectuée par le serveur ou pour la traduction en temps réel
G06F 40/284 - Analyse lexicale, p.ex. segmentation en unités ou cooccurrence
Aspects of the disclosure relate to reagents, compositions, kits, and methods associated with liposome-mediated delivers7 of cargo in response to an environmental trigger. Some aspects of the present invention relate to treating a diseased cell, tissue, or organ using the reagents.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
15.
REPROGRAMMABLE TNPB POLYPEPTIDES WITH MAZE DOMAINS AND USES THEREOF
Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel TnpB polypeptides and a reprogrammable targeting nucleic acid component and methods and application of use are provided.
A reactor system and method for oxidizing methane can include an environmentally friendly catalyst material that converts methane to an oxidized product at low temperatures and concentrations, for example, to reduce or eliminate methane in coal mine air, dairy barns, oil and gas fields, and direct air conversion applications.
Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen/immune receptor interactions, in a single-cell format.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
A Rogowski-style current sensor includes a twisted pair of wires or cables formed into a coil. A second coil formed from another pair of wires or cables, twisted in the opposite direction, may be placed alongside, but not necessarily immediately adjacent to, the first coil, and the signals from each twisted pair may be added or subtracted to measure the enclosed current or a diamagnetism. When the current to be measured is a plasma current in a tokamak, the current sensor may be placed behind shielding tiles on the inner wall of a vacuum vessel that contains the plasma. Another current sensor may be placed on an external wall of the vacuum vessel, and the outputs subtracted to measure a current flowing through only the vessel itself.
G01R 15/18 - Adaptations fournissant une isolation en tension ou en courant, p.ex. adaptations pour les réseaux à haute tension ou à courant fort utilisant des dispositifs inductifs, p.ex. des transformateurs
G01R 19/00 - Dispositions pour procéder aux mesures de courant ou de tension ou pour en indiquer l'existence ou le signe
19.
CARBON ELECTRODES WITH SPATIAL GRADIENTS IN POROSITY FOR HIGH-POWER REDOX FLOW BATTERIES
The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 20/30 - Détection de sites de liaison ou de motifs
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
C12N 9/96 - Stabilisation d'une enzyme par formation d'un adduct ou d'une composition; Formation de conjugaisons d'enzymes
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
22.
ARTICLES AND METHODS FOR PROCESSING SCRAP ALUMINUM
Articles and methods for processing aluminum are generally described. The aluminum can include compositions of gallium and/or indium such that the aluminum is activated to react with water.
B09B 3/80 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif impliquant une étape d'extraction
C22B 7/00 - Mise en œuvre de matériaux autres que des minerais, p.ex. des rognures, pour produire des métaux non ferreux ou leurs composés
The present disclosure describes photonic materials that reversibly change color in response to the material being stretched or otherwise mechanically deformed.
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
24.
MICRO MAGNETIC RESONANCE RELAXOMETRY (MRR) FOR RAPID AND NON-INVASIVE DETECTION OF IPSC QUALITY AND DIFFERENTIATION
G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire
G01R 33/44 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance magnétique nucléaire [RMN]
SINGAPORE-MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY CENTRE (Singapour)
Inventeur(s)
Han, Jongyoon
Chew, Sing Yian
Nguyen, Tan Dai
Tan, Zu Yao, Jerome
Jeon, Hyungkook
Roxby, Daniel, Ninio
Abrégé
The invention relates to methods and devices for size-based separation of undifferentiated cells from a population of cells using curvilinear microfluidic channels. The curvilinear microfluidic channels may be a spiral microfluidic channels. The differentiated cells are spinal cord progenitor cells (SCPCs), neural progenitor cells (NPCs) and/or cells differentiated therefrom. The method may comprise flowing an input population of cells through first and second sequentially connected and fluidically communicating curvilinear microfluidic channels, wherein the first channel is coupled to an inlet and the second channel is coupled to one or more outlets, wherein the first curvilinear microfluidic channel has a smaller cross-sectional area than the second curvilinear microfluidic channel.
Methods and systems for the fabrication of composite materials are generally described. Certain inventive methods and systems can be used to fabricate composite materials with few or no defects. According to certain embodiments, composite materials are fabricated without the use of an autoclave. In some embodiments, composite materials are fabricated in low pressure environments.
What is described herein is a device for sensing a target, comprising a planar array of unique stochastic sensors, wherein each sensor is weakly cross-reactive with a unique determinant on the target; a means for capturing electrical signals from each sensor and the temporal duration of each signal; and a means for analyzing the cumulative signals from the array of stochastic sensors, and optionally further comprising a computer system for processing an algorithm for identifying the target based on the electrical signals from the sensors of the device.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
28.
SYSTEMS AND METHODS FOR TRAINING A SCENE SIMULATOR USING REAL AND SIMULATED AGENT DATA
System, methods, and other embodiments described herein relate to training a scene simulator for rendering 2D scenes using data from real and simulated agents. In one embodiment, a method includes acquiring trajectories and three-dimensional (3D) views for multiple agents from observations of real vehicles. The method also includes generating a 3D scene having the multiple agents using the 3D views and information from simulated agents. The method also includes training a scene simulator to render scene projections using the 3D scene. The method also includes outputting a 2D scene having simulated observations for a driving scene using the scene simulator.
G09B 9/042 - Simulateurs pour l'enseignement ou l'entraînement pour l'enseignement de la conduite des véhicules ou autres moyens de transport pour l'enseignement de la conduite des véhicules terrestres avec une simulation dans un véhicule réel
G09B 9/05 - Simulateurs pour l'enseignement ou l'entraînement pour l'enseignement de la conduite des véhicules ou autres moyens de transport pour l'enseignement de la conduite des véhicules terrestres la vue à partir d'un véhicule étant simulée
29.
SYSTEM AND METHODS FOR MEASUREMENT OF PARAMETERS SUCH AS INTRACRANIAL PRESSURE
Systems and methods related to determination of patient parameters such as intracranial pressure (ICP), intracranial compliance (ICC), and cerebrovascular resistance (CVR) are provided. In some instances, the parameters are determined based at least in part on measures two or more parameters related to distension of a vessel and blood flow through the vessel (e.g., arterial blood pressure and cerebral blood flow). In some instances, the parameters are determined based at least in part on measurements performed using one or more probes (e.g., a single probe) at a single patient site. The systems and method described may, in some instances, facilitate determination of these parameters non-invasively and/or at a point-of-care.
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
30.
METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OFPEPTIDE-MHC TARGETING BINDING PROTEINS
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR T cells capable of binding to peptides bound to specific MHC alleles.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p.ex. séquençage par hybridation [SBH]
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/10 - Ploïdie ou détection du nombre de copies
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
G16B 40/00 - TIC spécialement adaptées aux biostatistiques; TIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p.ex. extraction de connaissances ou détection de motifs
The present invention presents improved systems and methods for performing multi-photon lithography. A line-scanning temporally focused two-photon lithography (LS-TFTPL) technique is capable of patterning three-dimensional structures with high throughput. An example LS-TFTPL system may include a pulsed laser, first optical components for expanding light pulses into an elongated or line cross section, a digital micromirror device for modulating the light pulses with a linear pattern and dispersing spectral components of the modulated light pulses, and second optical components for focusing the dispersed spectral components of the modulated light pulse at a line in or on a target material. The focused spectral components may alter the target material within selected voxels along the line, where the selected voxels spatially correspond to the linear pattern.
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
B29C 64/135 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p.ex. par irradiation globale combinée avec un masque la source d’énergie étant concentrée, p.ex. lasers à balayage ou sources lumineuses focalisées
Described in certain example embodiments herein are programmable nuclease¬ peptidase compositions, systems, and methods for the manipulation of nucleic acids and/or polypeptides. In some embodiments, the programmable nuclease-peptidase composition comprises a repeat-associated mysterious protein (RAMP) polypeptide; a guide molecule capable of forming a RAMP-guide molecule complex with the RAMP polypeptide and directing sequence specific binding of the complex to a target polynucleotide; and a peptidase capable of binding to the RAMP polypeptide, the guide molecule, or further complexing with the RAMP-guide molecule complex, wherein binding of the RAMP-guide molecule complex to the target polynucleotide initiates binding and/or interaction of the peptidase with a target polypeptide.
34.
NOVEL COMBINATION OF RIFAXIMIN AND CLARITHROMYCIN FOR TREATING MULTIDRUG-RESISTANT MYCOBACTERIUM ABSCESSUS
The present invention relates to a novel synergistic combination of rifaximin and clarithromycin. The invention also relates to a kit comprising such combination, and such combination for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseases caused by pathogenic mycobacteria such as clarithromycin-resistant and clarithromycin non-resistant non-tuberculosis mycobacteria.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
What is described herein is a device for sensing a target, comprising a planar array of unique stochastic sensors, wherein each sensor is weakly cross-reactive with a unique determinant on the target; a means for capturing electrical signals from each sensor and the temporal duration of each signal; and a means for analyzing the cumulative signals from the array of stochastic sensors, and optionally further comprising a computer system for processing an algorithm for identifying the target based on the electrical signals from the sensors of the device.
36.
MICROFILTRATION DEVICE, METHOD OF PREPARING THE SAME, METHOD OF SEPARATING BIOLOGICAL MATERIAL AND A KIT
Disclosed herein is a microfiltration device comprising a microfilter coated with a positively charged degradable layer and a method of preparing the microfiltration device. In particular, the positively charged degradable layer comprises a polymer substrate and a cation, and wherein the polymer substrate is alginate gel and the cation is calcium (II). Also disclosed is a method of separating a biological material from a sample using said microfiltration device and a kit comprising said microfiltration device. In particular, the biological material is a negatively charged bacteria, fungus, or virus. The microfiltration device and method of separating a biological material described herein demonstrate good compatibility with various downstream analysis techniques.
B01D 71/74 - Matériaux macromoléculaires naturels ou leurs dérivés
C12Q 1/24 - Méthodes d'échantillonnage, d'inoculation ou de développement d'un échantillon; Méthodes pour isoler physiquement un micro-organisme intact
37.
DNA NUCLEASE GUIDED TRANSPOSASE COMPOSITIONS AND METHODS OF USE THEREOF
The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements. Specifically, the disclosure provides an engineered composition comprising: a programmable DNA-binding protein and two or more Tn7-like transposition proteins, wherein at least one of the Tn7-like transposition proteins is connected to the DNA-binding protein or otherwise capable of forming a complex with the DNA-binding protein, wherein the DNA-binding protein comprising a Cas protein including a Cas12k protein, and wherein two or more Tn7-like transposition proteins consisting of TnsB, TnsC, and TniQ.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
An orbital tensile drive is herein disclosed, along with systems and methods associated therewith. The orbital tensile drive uses a tensile element that is conveyed around a static, fixed shaft and a rotating output shaft. This is facilitated via multiple orbiting idler pulleys that are mounted to an orbiter body. The static and rotating shafts, as well as the orbiting assembly, share a common axis. Input rotation to the orbiter body is transformed into lower-speed, higher-torque rotation at the rotating output shaft. The present invention has many potential applications including, but not limited to, robotics.
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).
Compositions are provided that include a first product with a physical unclonable function (PUF) tag including silk particles conformably and directly attached to the first product, wherein the PUF tag cannot be reattached to a second product once removed from the first product.
Rapid charging and high energy density are valuable battery attributes. However, high performance batteries with both of these attributes can be difficult to achieve. Conventional high performance batteries rely on metal-based electrodes including materials that can be difficult to source. Batteries with high capacity, even during rapid charge-discharge cycling, are herein provided. According to some embodiments, a battery provided herein includes an organic electrode and an organic, non-aqueous solvent system. Constituents of the organic electrode may be additionally advantaged by the comparative ease with which they may be sourced.
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
H01M 4/13 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication
C07C 49/587 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle
H01M 4/60 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés organiques
44.
FABRICATION OF POLYMERIC MICRONEEDLES WITH HOLLOW AND POROUS TIPS VIA A SIMPLE MICROMOLDING PROCESS ASSISTED BY IONIC SALTS
What is disclosed herein is a composition comprising a mixture of a soluble polymer in a solvent and an immiscible highly-soluble molecule in the same solvent, wherein the immiscible highly-soluble molecule substitutes inorganic ions, wherein the solubility of the immiscible highly-soluble molecule is more than 50 times higher than the solubility of the soluble polymer in the solvent, and wherein the soluble polymer can be cross linked to become insoluble during a material fabrication process. Also disclosed is a method of making the composition, a microneedle comprising the composition, methods for making a silk protein nanostructure array, and silk protein nanostructure arrays.
222 in contact with the composite second electrode; where the solid-state electrolyte is disposed between the first electrode and the composite second electrode. Methods of making the battery and methods of producing electricity with the battery are also described.
46.
FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS FOR SATURATING MUTAGENESIS OF NON-CODING ELEMENTS, COMPOSITIONS, METHODS, LIBRARIES AND APPLICATIONS THEREOF
The application relates to a deep scanning mutagenesis library to interrogate phenotypic changes in a population of cells comprising a plurality of CRISPR-Cas system guide RNAs targeting genomic sequences within at least one continuous genomic region, wherein the guide RNAs target at least 100 genomic sequences upstream of a PAM sequence for every 1000 base pairs within the continuous genomic region and methods for their use.
This disclosure provides systems, methods, and compositions for site specific genetic engineering comprising the use of CRISPR effectors and trans-splicing. The disclosure also relates to methods of using the systems and compositions for treating diseases as well as diagnostics.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A method is directed to continuously, non-invasively, and directly measuring blood pressure, and includes providing a calibrated measurement device having a blood-flow control balloon and a sensor array. The method further includes placing the sensor array in a non-invasive manner over the surface of a patch of skin connected to an artery by adjoining soft tissues and inflating the blood-flow control balloon with a controlled amount of pressure. In response to the inflating of the blood-flow control balloon, changes in the artery geometry and forces are detected, via the sensor array, during a heartbeat cycle. The changes correspond to spatio-temporal signals from the artery or in the adjoining soft tissues. The spatio-temporal signals are measured and processed, via a controller, to determine blood-pressure parameters.
A61B 5/022 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p.ex. contre la peau; Ophtalmodynamomètres
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
A61B 8/08 - Détection de mouvements ou de changements organiques, p.ex. tumeurs, kystes, gonflements
B01D 53/22 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 53/46 - Elimination des composants de structure définie
Glycan-binding proteins, and compositions thereof, are generally described, including methods of making and using such proteins. The proteins may include scaffolds based on easily evolvable DNA-binding proteins, with binding sites able to specifically bind to mono- or disaccharides, such as monosaccharide-binding determinants, disaccharide-binding determinants, more complex carbohydrates, etc. In certain aspects, a protein may be generated starting from a small DNA-binding protein, such as Sso7d. Such glycan-binding proteins may have numerous applications, including in enzyme-linked immunosorbent assays (ELISAs), glycan characterization, cell selection, flow cytometry, histology, imaging, arrays, affinity purification, enzyme-linked visualization, binding to a target for pharmaceutical purposes, etc.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
51.
Integrating Biopolymer Design with Physical Unclonable Functions for Anticounterfeiting and Product Traceability
Compositions are provided that include a first product with a physical unclonable function (PUF) tag including silk particles conformably and directly attached to the first product, wherein the PUF tag cannot be reattached to a second product once removed from the first product.
H04L 9/32 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Hwang, Theresa
Keating, Amy E.
Ilunga, Meucci
Parker, Sara
Mouneimne, Ghassan
Hill, Samantha
Abrégé
Peptides that selectively bind ENAH (MENA) are described. The peptides are useful for treating certain cancers, such as triple negative breast cancer and for reducing resistance to taxane therapy.
Systems and methods for electrochemical target species separation are described herein. In some embodiments, a target species can be transported, in response to an applied voltage, from a fluid in a first electrically conductive tube (e.g., a tubular electrode) that has a low concentration of the target species to a fluid in a second electrically conductive tube (e.g., a tubular electrode) that has a high concentration of the target species. The transport of the target species may involve the diffusion of the target species through porous walls of the first and second tube. In some embodiments, the target species comprises gases such as acid gases (some of which may be commonly exhausted from powerplants and/or industrial processes).
B01D 53/32 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
INSTITUTO TECHNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY (Mexique)
Inventeur(s)
Boriskina, Svetlana V.
Chen, Gang
Lozano Sanchez, Luis Marcelo
Alberghini, Matteo
Abrégé
The present disclosure generally relates to textiles that are optimized to maximize moisture wicking and evaporative performance thereof. In some embodiments, raw polyethylene (PE) powder can be extruded into fibers that can be modified by oxidation along a surface thereof to increase hydrophilicity of the surface. Once sufficiently oxidized, the fibers can be bundled to form multi-filament yarns that can then be spun, weaved, knitted, and/or otherwise associated with one another to form a polyethylene fabric. The PE fibers can be further modified to increase a capillary force of the bundle, thereby further increasing hydrophilicity of the resulting fabric. Engineering of the capillary force can be performed by optimizing one or more of a fiber size, a density, or a cross-section of the fibers and/or the bundles. The resultant fabric can exhibit a strong weight reduction, stain resistance, and drying capabilities, among other capabilities.
D06M 10/00 - Traitement physique des fibres, fils, filés, tissus ou articles fibreux faits de ces matières, p.ex. ultrasonique, effet corona, irradiation, courants électriques ou champs magnétiques; Traitement physique combiné avec le traitement avec des composés ou des éléments chimiques
D06M 10/02 - Traitement physique des fibres, fils, filés, tissus ou articles fibreux faits de ces matières, p.ex. ultrasonique, effet corona, irradiation, courants électriques ou champs magnétiques; Traitement physique combiné avec le traitement avec des composés ou des éléments chimiques ultrasonique ou sonique; Effet corona
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are stmctural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formulation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
56.
CERTIFICATION-BASED ROBUST TRAINING BY REFINING DECISION BOUNDARY
A computer implemented method for certifying robustness of image classification in a neural network is provided. The method includes initializing a neural network model. The neural network model includes a problem space and a decision boundary. A processor receives a data set of images, image labels, and a perturbation schedule. Images are drawn from the data set in the problem space. A distance from the decision boundary is determined for the images in the problem space. A re-weighting value is applied to the images. A modified perturbation magnitude is applied to the images. A total loss function for the images in the problem space is determined using the re-weighting value. A confidence level of the classification of the images in the data set is evaluated for certifiable robustness.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for identification of anatomical landmarks from image data. The image analysis provides for guidance for insertion of a cannulation system into an airway of a subject which may be accomplished by a non-expert based upon the guidance provided. The system further enables a single person to perform the cannulation rather than the typical 2 or more people. The guidance may include an indicator or a mechanical guide to guide a user for inserting the cannulation system into a subject to penetrate the airway of interest.
Provided herein are peptides that bind Mcl-1. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut (Allemagne)
Charité - Universitätsmedizin Berlin (Allemagne)
Inventeur(s)
Birnbaum, Michael
Huisman, Brooke
Romagnani, Chiara
Rückert, Timo
Abrégé
Peptides capable of binding to HLA-E and affecting immune cell activity are provided. Such peptides can selectively activate NKG2C+ immune cells such as natural killer (NK) cells and/or can inhibit NKG2A+ cells to decrease or suppress immune cell responses. Methods of use of the peptides are also disclosed, for instance, for treating or inhibiting the development or progression of a multitude of illnesses and conditions, including autoimmune disease, infectious disease such as viral or bacterial infection, and proliferative disorders such as cancer.
According to one aspect of the disclosure, a mobile augmented reality (AR) system can include: a receiver configured to receive radio frequency (RF) signals from one or more items located within an environment; a tracking module configured to generate tracking data responsive to a location of the system within the environment over time; a display device; and one or more processors configured to determine a location of at least one of the one or more items within the environment using the received RF signals and the tracking data, and generate a visual representation of the location of the at least one item for display on the display device.
A wind turbine generator includes a stator having a plurality of high-temperature superconducting coils. A current is driven through the high-temperature superconducting coils to produce a magnetic field. A rotor comprising one or more phase coils is physically coupled to a wind turbine. As the wind turbine turns the rotor, current is induced in the one or more phase coils to produce electrical power. The phase coils may include conductive material, superconducting material, and/or high-temperature superconducting material.
Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more LTR retroelement polypeptides for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more LTR retroelement polypeptides for forming a delivery vesicle may comprise two or more of an LTR retroelement gag protein, a retroelement envelope protein, a an LTR retroelement reverse transcriptase, or a combination thereof. The LTR retroelement polypeptide alone, the LTR retroelement envelope protein alone, or both the LTR retroelement-derived polypeptide and LTR retroelement envelope protein may be endogenous.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorders.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4409 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 4, p.ex. isoniazide, iproniazide
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
65.
COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF
The disclosure features amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR)ligand and a lipid. The disclosure also features compositions and methods of using the same, for example, to stimulate proliferation of CAR expressing cells.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
66.
CONSTRUCTS FOR CONTINUOUS MONITORING OF LIVE CELLS
The present invention provides for methods to obtain multiple information-rich samples at different time points from the same cell while minimally disrupting the cell. The subject matter disclosed herein is generally related to nucleic acid constructs for continuous monitoring of live cells. Specifically, the subject matter disclosed herein is directed to nucleic acid constructs that encode a fusion protein and a construct RNA sequence that induce live cells to self-report cellular contents while maintaining cell viability. The present invention may be used to monitor gene expression in single cells while maintaining cell viability.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
67.
Protection of Next-Generation Probiotics during Processing
Prokaryotic cells having a metal-phenolic network coating are disclosed, as are compositions including such cells, methods for their use, and methods for producing such cells.
A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p.ex. un ion inorganique complexé avec l’ingrédient actif
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
68.
Software and Methods for Controlling Neural Responses in Deep Brain Regions
Techniques for non-invasively controlling targeted neural activity of a subject are provided herein. The techniques include applying a stimulus input to the subject, the stimulus input being formed by a deep artificial neural network (ANN) model and being configured to elicit targeted neural activity within a brain of the subject. The stimulus input may be a pattern of luminous power generated by the deep ANN model and applied to retinae of the subject. The stimulus input may be generated by the deep ANN model based on a mapping of the subject's neural responses to neurons of the deep ANN model.
A61M 21/00 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscience; Dispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p.ex. pour mettre en état d'hypnose
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/388 - Modalités, c. à d. méthodes diagnostiques spécifiques Études de la conduction nerveuse, p.ex. détection du potentiel d’action d’un nerf périphérique
69.
POROUS MEDIUM WITH ADJUSTABLE FLUID PERMEABILITY AND ASSOCIATED SYSTEMS AND METHODS
The present disclosure is related to porous media with adjustable fluid permeabilities and related systems and methods. In certain cases, the fluid permeability of a porous medium can be adjusted by applying an electrical potential to the porous medium. In some such cases, the application of the electrical potential to the porous medium results in the deposition of material over or the removal of material from the porous medium. Also disclosed herein are systems and methods for capturing species (e.g., acid gases) in which porous media with adjustable fluid permeabilities are used, for example, to control the flow of fluid into and out of a medium used to capture the species.
B01D 53/32 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
B01D 53/22 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
Polymeric electro spray emitters and related methods are generally described. In some embodiments, an emitter may be made from an ionic electro active polymer. The composition of the electro spray emitters described herein may enable the transport of ions and/or liquid ion sources, such as an ionic liquid or room temperature molten salt, through the bulk of the polymeric emitter. In some embodiments, the described emitters may be fabricated using a mixture of an ionic electroactive polymer, a solvent, and a liquid ion source to at least partially mitigate swelling effects of the polymer emitter that may otherwise occur when the one or more emitters are exposed to the liquid ion source during operation.
This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA e analytical applications, such as sequencing applications.
The present invention relates to the analysis of complex single cell sequencing libraries. Disclosed are methods for enrichment of library members based on the presence of cell-of origin barcodes to identify and concentrate DNA that is relevant to interesting cells or components that would be expensive or difficult to study otherwise. Also, disclosed are methods of capturing cDNA library molecules by use of CRISPR systems, hybridization or PCR. The present invention allows for identifying the properties of rare cells in single cell RNA-seq data and accurately profile them through clustering approaches. Further information on transcript abundances from subpopulations of single cells can be analyzed at a lower sequencing effort. The methods also allow for linking TCR alpha and beta chains at the single cell level.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C40B 40/06 - Bibliothèques comprenant des nucléotides ou des polynucléotides ou leurs dérivés
C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
C40B 50/06 - Procédés biochimiques, p.ex. utilisant des enzymes ou des micro-organismes viables entiers
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
A reticle transport system having a magnetically levitated transportation stage is disclosed. Such a system may be suitable for use in vacuum environments, for example, ultra-clean vacuum environments. A magnetic levitated linear motor functions to propel the transportation stage in a linear direction along a defined axis of travel and to magnetically levitate the transportation stage
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
H02K 41/03 - Moteurs synchrones; Moteurs pas à pas; Moteurs à réluctance
75.
SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE)
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
Quantum information processing involves entangling large numbers of qubits, which can be realized as defect centers in a solid-state host. The qubits can be implemented as individual unit cells, each with its own control electronics, that are arrayed in a cryostat. Free-space control and pump beams address the qubit unit cells through a cryostat window. The qubit unit cells emit light in response to these control and pump beams and microwave pulses applied by the control electronics. The emitted light propagates through free space to a mode mixer, which interferes the optical modes from adjacent qubit unit cells for heralded Bell measurements. The qubit unit cells are small (e.g., 10 μm square), so they can be tiled in arrays of up to millions, addressed by free-space optics with micron-scale spot sizes. The processing overhead for this architecture remains relatively constant, even with large numbers of qubits, enabling scalable large-scale quantum information processing.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
77.
ACTIVE PIEZOELECTRIC SHEET WITH PIEZOELECTRIC MICROSTRUCTURES
An active acoustic system includes a thin-film sheet having an array of piezoelectric microstructures embossed in the film. Each piezoelectric microstructure may act as a speaker and/or a microphone. A control circuit is configured to individually address the piezoelectric microstructures to provide a separate voltage signal to, or receive a separate voltage signal from, each piezoelectric microstructure.
H04R 1/40 - Dispositions pour obtenir la fréquence désirée ou les caractéristiques directionnelles pour obtenir la caractéristique directionnelle désirée uniquement en combinant plusieurs transducteurs identiques
The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
22 masks (110) on 2-inch substrates (100) to define selective or confined growth areas. Each growth area or trench (102) is just a few microns wide and is filled with a single-domain ML (124) before the second set of nuclei (132) is introduced. Growing the second set of nuclei (132) within the trenches yields an array of single-domain bilayers (124, 134) at the 2-inch wafer scale. Devices made with the single-domain bilayers exhibit excellent performance over the entire wafer.
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
C23C 14/22 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le procédé de revêtement
C23C 16/30 - Dépôt de composés, de mélanges ou de solutions solides, p.ex. borures, carbures, nitrures
Systems and methods for redox-driven gas separation are generally described. What is described herein is a method, apparatus, and system for the photoelectrochemical capture of acid gases from a fluid gas mixture, as well as the photoelectrochemical release of the captured acid gas into a concentrated stream of the acid gas. Certain embodiments are related to photoelectrochemical systems comprising a photoelectrode which, upon illumination with light, induces oxidation or reduction of redox-active species in an electrolyte solution in the system, that, when brought into contact with a fluid gas mixture including an acid gas, capture acid gases from the fluid gas mixture by raising the pH of the electrolyte solution or chemically binding to the acid gas molecule. The methods, apparatuses, and systems described herein are useful in carbon capture and pollution mitigation applications, and in direct use of solar energy to drive the capture and release of acid gases from fluid gas mixtures.
B01D 53/22 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 53/00 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols
Bi-modal propulsion systems and related methods are generally described. In some embodiments, a bi-modal propulsion system may employ a single propellant for both chemical thruster(s), operating at elevated pressures, and electrical thruster(s) (e.g., electro spray thruster), operating at reduced pressures. The propellant pressure may be reduced to a desired operational range of the electrical thruster(s) using any appropriate construction including, for example, capillaries configured to reduce the pressure of the propellant to an operational range of the electrical thruster(s). In some embodiments, the reduced pressure of the propellant may be lower than a vapor pressure of at least one volatile component of the propellant, leading to the formation of “bubbles” within the propellant line. The presence of alternating gas and liquid phases along a flow path between a propellant tank and the electrical thruster(s) may help to electrically insulate the electrical thruster from the rest of the system.
A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p.ex. leur création ou leur transmission
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/16 - Dispositifs pour la psychotechnie; Test des temps de réaction
G06Q 10/101 - Création collaborative, p.ex. développement conjoint de produits ou de services
G06Q 50/00 - Systèmes ou procédés spécialement adaptés à un secteur particulier d’activité économique, p.ex. aux services d’utilité publique ou au tourisme
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
83.
AUTOMATED METHODS FOR SCALABLE, PARALLELIZED ENZYMATIC BIOPOLYMER SYNTHESIS AND MODIFICATION USING MICROFLUIDIC DEVICES
Methods for the automated template-free synthesis of user-defined sequence controlled biopolymers using microfluidic devices are described. The methods facilitate simultaneous synthesis of up to thousands of uniquely addressed biopolymers from the controlled movement and combination of regents as fluid droplets using microfluidic and EWOD-based systems. In some forms, biopolymers including nucleic acids, peptides, carbohydrates, and lipids are synthesized from step-wise assembly of building blocks based on a user-defined sequence of droplet movements. In some forms, the methods synthesize uniquely addressed nucleic acids of up to 1,000 nucleotides in length. Methods for adding, removing and changing barcodes on biopolymers are also provided. Biopolymers synthesized according to the methods, and libraries and databases thereof are also described. Modified biopolymers, including chemically modified nucleotides and biopolymers conjugated to other molecules are described.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
NTT RESEARCH, INC. (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Nehra, Rajveer
Yanagimoto, Ryotatsu
Hamerly, Ryan
Ng, Edwin
Marandi, Alireza
Mabuchi, Hideo
Abrégé
Methods and systems are presented for using optical parametric amplifiers in various ways that enhance a native quadratic coupling strength so that a photonic component of interest can be measured or otherwise observed without demolishing the component of interest at a system output. For example such components may include a number of signal Bogoliubov excitations, a pump modular quadrature, or a signal quadrature squared.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
G06N 10/60 - Algorithmes quantiques, p.ex. fondés sur l'optimisation quantique ou les transformées quantiques de Fourier ou de Hadamard
G06N 10/80 - Programmation quantique, p.ex. interfaces, langages ou boîtes à outils de développement logiciel pour la création ou la manipulation de programmes capables de fonctionner sur des ordinateurs quantiques; Plate-formes pour la simulation ou l’accès aux ordinateurs quantiques, p.ex. informatique quantique en nuage
85.
Confined Growth of 2D Materials and Their Heterostructures
Two-dimensional (2D) materials and their heterostructures show a promising path for next generation electronics. Nevertheless, there are challenges with (i) controlling monolayer (ML)-by-ML 2D material growth, (ii) maintaining single-domain growth, and (iii) controlling the number of layers and crystallinity at the wafer-scale. The deterministic confined growth techniques disclosed here address these challenges simultaneously to produce wafer-scale single-domain 2D MLs and their heterostructures on arbitrary substrates. The growth of the first nuclei is confined by patterning SiO2 masks on 2-inch substrates to define selective or confined growth areas. Each growth area or trench is just a few microns wide and is filled with a single-domain ML before the second set of nuclei is introduced. Growing the second set of nuclei within the trenches yields an array of single-domain bilayers at the 2-inch wafer scale. Devices made with the single-domain bilayers exhibit excellent performance over the entire wafer.
Schemes are described for joint geometry and placement in superconducting magnets. According to some aspects, a joint may be implemented in a modular component of a superconducting magnet, such as a plate that includes a spiral superconducting path, with the joints providing electrically conductive connections between the superconducting paths of adjacent plates. A joint may be installed and coupled to the component (e.g., plate) after its fabrication, thereby providing freedom in design of both the joint and the component. In at least some cases, the joints may be arranged to be flush with a surface of the component after installation into the component so that neighboring instances of the components may be stacked flush with one another, thereby putting joints from the neighboring components into intimate contact with one another.
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
Embodiments disclosed herein provide a pan-tissue cell atlas of healthy and diseased subjects obtained by single cell sequencing. The present invention discloses novel markers for cell types. Moreover, genes associated with disease, including HIV infection and tuberculosis are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for controlling immune regulations and cell-cell communication of the cell types disclosed herein. In addition, novel cell types and methods of quantitating, detecting and isolating the cell types are disclosed.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
89.
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
This disclosure provides systems, methods, and compositions for site specific genetic engineering comprising the use of CRISPR effectors and trans-splicing. The disclosure also relates to methods of using the systems and compositions for treating diseases as well as diagnostics.
The present disclosure provides a protein which is composed of a sequence including one amino acid sequence among the following (a)-(c) and forms a complex with a guide RNA: (a) an amino acid sequence which includes an amino acid sequence composed of at least amino acid numbers 198-614 in the amino acid sequence represented by SEQ ID NO: 1, and includes a substitution of one or both of E172 and E297; (b) an amino acid sequence in which at least one amino acid is deleted, inserted, substituted, or added in portions other than amino acid numbers 172 and 297 in the amino acid sequence represented by (a); and (c) an amino acid sequence which shares an identity of at least 80% with portions other than amino acid numbers 172 and 297 in the amino acid sequence represented by (a). This protein is a Cas13bt3 variant having improved efficiency and specificity.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
92.
COMPOSITIONS AND METHODS FOR MITIGATING AGGREGATION OF AND RECYCLING OF NANOSCALE CATALYSTS
What is described herein are nanostructures, compositions comprising the nanostructures, and related methods. In some embodiments, the nanostructure comprises an aramid amphiphile and a functional moiety associated with the aramid amphiphile. In some cases, the functional moiety may be configured to perform catalysis. According to some embodiments, a nanostructure comprising an aramid amphiphile, comprising a cysteine charged group; and a functional moiety selected from the group consisting of a nanoparticle, an enzyme, and a metal complex; wherein the functional moiety is bound to the aramid amphiphile through the cysteine is described. Also disclosed are uses of the nanostructures as catalysts in chemical reactions.
B01J 31/00 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
B01J 31/06 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques contenant des polymères
Disclosed are methods for full morphological labeling of individual neurons from any species or cell type for subsequent cell-delineated protein analysis. These methods, which combines patch-clamp electrophysiology with epitope-preserving magnified analysis of proteome (eMAP), additionally allow for correlation of physiological properties with subcellular protein expression.
A61B 5/053 - Mesure de l'impédance ou de la conductivité électrique d'une partie du corps
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
The present disclosure provides polymers comprising nl2 instances of a moiety of Formula (I): or a salt thereof. The present disclosure also provides methods of preparing the polymers and methods of degrading the polymers. Contacting the polymers with a fluoride nucleophile (e.g., tetrabutylammonium fluoride) or acid (e.g. octanoic acid) may degrade the polymers by cleaving the O-Si bonds. The polymers may be useful as degradable polymers, adhesives, coatings, elastomers, sealants, flexible foams, or structural materials.
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
C08G 18/70 - Polymérisats d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs caractérisés par les isocyanates ou isothiocyanates utilisés
The present invention describes photoluminescent apparatuses or colour filters (100a,100b,100c,100d) and methods (1000a,1000b) for manufacturing. A photoluminescent (PL) or quantum dot (QD) material (100) fills a pattern of trenches (40,42) formed on a surface or on opposite surfaces of an optically transparent substrate (20), being cured and sealed by an optically transparent cover (22); in another embodiment, the PL or QD material (100) are cured and sealed when two patterned optically substrates (20) are bonded together. Sealing of the PL or QD material in the trenches (40,42) preserves the optical and performance stability of these colour filters. These colour filters (100a, . . . 100d) are suitable for use in next generation UHD display screens or lighting applications.
B01D 29/86 - Manipulation du gâteau de filtration dans le filtre pour des raisons autres que la régénération pour retarder le dépôt du gâteau sur le filtre pendant la filtration, p.ex. en utilisant des agitateurs
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
B01D 29/05 - Filtres à éléments filtrants stationnaires pendant la filtration, p.ex. filtres à aspiration ou à pression, non couverts par les groupes ; Leurs éléments filtrants avec des éléments filtrants plats avec des supports
B01D 29/60 - Filtres à éléments filtrants stationnaires pendant la filtration, p.ex. filtres à aspiration ou à pression, non couverts par les groupes ; Leurs éléments filtrants combinés dans une même structure à des dispositifs de commande de la filtration
B01D 35/18 - Chauffage ou refroidissement des filtres
98.
Parallel Microcavity Trimming by Structured-Laser Illumination
Methods and systems are described for precisely adjusting characteristics of microfabricated devices after device fabrication. The adjustments can be carried out in parallel on a plurality of the microfabricated devices. By carrying out the adjustment process, uniformity of feature sizes to a few picometers (one standard deviation) and corresponding uniformity of operating characteristics for a plurality of microfabricated devices are possible.
G02F 1/025 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments à semi-conducteurs ayant au moins une barrière de potentiel, p.ex. jonction PN, PIN dans une structure de guide d'ondes optique
Methods for consolidating scrap metal into a sheet metal for subsequent use are disclosed. The methods can include forming a container, such as a pipe or tube, out of a sheet metal such that one end of the container is closed and the other is open. The scrap metal can then be placed into the container, even without pre-treating the scrap metal. Oxygen can be removed from an internal, receiving cavity of the formed container, such as by introducing a gas such as argon or nitrogen, into the container, and, if desired, the open end of the container can be sealed. The combination of the container made from the sheet metal and the scrap metal can be roll bonded to form a consolidated sheet metal that includes both the original sheet metal and the scrap metal. Systems for performing these methods, as well as the consolidated metal, are also described.
Described herein are techniques for designing proteins for binding to a target. In some embodiments, the techniques include: obtaining an amino acid sequence for a candidate protein that binds to the target with a candidate binding affinity; determining, for proteins in a set of proteins, probabilities that binding affinities between the proteins and the target are greater than the candidate binding affinity, and identifying a subset of the set of proteins based on the determined probabilities. Determining a first probability that a first binding affinity between a first protein and the target is greater than the candidate binding affinity may include: processing a first amino acid sequence of the first protein using a trained machine learning model to obtain a first output indicative of the first binding affinity; and determining the first probability using the first output indicative of the first binding affinity between the first protein and the target.